OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TRPM58

Aesthetic Connect PCL

Healthcare Facilities & ServicesVerified

Aesthetic Connect PCL maintains a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is characterized by a current ratio of 13.71, suggesting robust short-term liquidity. However, the company reports negative net cash of -8.14 million THB, which raises concerns about its immediate liquidity position. In terms of profitability, the company's return on equity (ROE) is 2.5%, and its return on assets (ROA) is 2.36%, both of which are below the industry median for Healthcare Facilities & Services. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant revenue growth projected in the next fiscal year. The company's capital expenditure of -30.09 million THB indicates a net outflow, which may be used for expansion or asset replacement. The company faces moderate liquidity risk due to its negative net cash position, which could limit its ability to fund operations without external financing. The risk assessment also notes a low dilution potential, suggesting that the company is unlikely to issue additional shares in the near term. Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly impact the company's operations or financial performance. The company's financial statements remain consistent with prior periods, with no major anomalies reported.

30-day price · TRPM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAesthetic Connect PCL
TickerTRPM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Aesthetic Connect PCL provides pharmaceutical products and services, primarily generating revenue through the sale of medical and aesthetic treatments.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Aesthetic Connect PCL maintains a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is characterized by a current ratio of 13.71, suggesting robust short-term liquidity. However, the company reports negative net cash of -8.14 million THB, which raises concerns about its immediate liquidity position. In terms of profitability, the company's return on equity (ROE) is 2.5%, and its return on assets (ROA) is 2.36%, both of which are below the industry median for Healthcare Facilities & Services. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant revenue growth projected in the next fiscal year. The company's capital expenditure of -30.09 million THB indicates a net outflow, which may be used for expansion or asset replacement. The company faces moderate liquidity risk due to its negative net cash position, which could limit its ability to fund operations without external financing. The risk assessment also notes a low dilution potential, suggesting that the company is unlikely to issue additional shares in the near term. Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly impact the company's operations or financial performance. The company's financial statements remain consistent with prior periods, with no major anomalies reported.
Key takeaways
  • Aesthetic Connect PCL maintains a conservative capital structure with minimal leverage.
  • The company's profitability metrics are below industry medians, indicating underperformance.
  • The company's liquidity position is mixed, with a strong current ratio but negative net cash.
  • Growth is expected to remain stable, with no significant revenue expansion projected.
  • The company is unlikely to face near-term dilution pressure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$147.3M
Gross profit$78.9M
Operating income$54.4M
Net income$43.2M
R&D
SG&A
D&A
SBC
Operating cash flow$28.1M
CapEx-$30.1M
Free cash flow$17.1M
Total assets$1.83B
Total liabilities$103.4M
Total equity$1.73B
Cash & equivalents-$8.1M
Long-term debt$11.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$427.6M$142.5M$112.7M$39.3M
FY-3$853.6M$342.3M$270.3M-$90.9M
FY-2$707.8M$245.4M$192.6M-$167.4M
FY-1$533.7M$169.6M$139.4M-$244.3M
FY0$471.7M$108.8M$87.2M-$191.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$470.3M$358.9M-$2.3M
FY-3$802.8M$569.3M-$369.6k
FY-2$1.80B$1.69B-$974.6k
FY-1$1.87B$1.72B-$3.4M
FY0$1.73B$1.62B-$3.5M
PeriodOCFCapExFCFSBC
FY-4$178.1M-$4.4M$39.3M
FY-3$301.7M-$314.8M-$90.9M
FY-2$206.8M-$73.0M-$167.4M
FY-1$120.0M-$294.1M-$244.3M
FY0$50.5M-$230.0M-$191.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$147.3M$54.4M$43.2M$17.1M
FQ-6$121.2M$33.0M$25.5M-$113.7M
FQ-5$131.8M$41.4M$38.0M-$59.3M
FQ-4$133.3M$40.8M$32.6M-$88.3M
FQ-3$106.6M$28.6M$21.4M-$76.5M
FQ-2$101.0M$20.6M$16.9M-$75.3M
FQ-1$121.7M$23.1M$18.6M$10.1M
FQ0$142.3M$36.5M$30.2M$19.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.83B$1.73B-$8.1M
FQ-6$1.75B$1.65B-$10.1M
FQ-5$1.79B$1.69B-$17.6M
FQ-4$1.87B$1.72B-$3.4M
FQ-3$1.85B$1.73B-$3.6M
FQ-2$1.72B$1.62B-$4.0M
FQ-1$1.69B$1.59B-$2.4M
FQ0$1.73B$1.62B-$3.5M
PeriodOCFCapExFCFSBC
FQ-7$28.1M-$30.1M$17.1M
FQ-6$35.9M-$68.1M-$113.7M
FQ-5$67.9M-$169.3M-$59.3M
FQ-4$120.0M-$294.1M-$88.3M
FQ-3-$38.8M-$101.4M-$76.5M
FQ-2-$28.6M-$195.8M-$75.3M
FQ-1-$473.1k-$211.5M$10.1M
FQ0$50.5M-$230.0M$19.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.73B
Net cash-$19.7M
Current ratio13.7
Debt/Equity0.0
ROA2.4%
ROE2.5%
Cash conversion65.0%
CapEx/Revenue-20.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTRPMActivity
Op margin36.9%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin29.4%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin53.5%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-20.4%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity1.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Observations
IR observations
Mean price target5.05 THB
Median price target5.05 THB
High price target5.05 THB
Low price target5.05 THB
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.30 THB
Last actual EPS0.25 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:43 UTC#038c9b6b
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 19:05 UTCJob: eb9e53ff